ASH Clinical News ACN_5.6_Full_Issue_Digital | Page 31

Today, cancer treatment requires a forward-thinking vision. The BiTE ® platform is engineered to deliver off-the-shelf immuno-oncology therapies that are designed to direct patients’ own T cells to target any tumor-specific antigen. 1,2 This groundbreaking technology activates the cytotoxic potential of T cells, with the hope of advancing the field of immuno-oncology for a better tomorrow. 1,2 Learn more at www.amgenoncology.com WE’RE BRINGING BiTE TO THE FIGHT ™ BiTE, Bispecific T Cell Engager. References: 1. Choi BD, Cai M, Bigner DD, et al. Bispecific antibodies engage T cells for antitumor immunotherapy. Expert Opin Biol Ther. 2011;11:843-853. 2. Baeuerle PA, Reinhardt C. Bispecific T-cell engaging antibodies for cancer therapy. Cancer Res. 2009;69:4941-4944. © 2019 Amgen Inc. All rights reserved. USA-ASCO-80001 4/19